The Latest Breaking News from Krystal Biotech

Krystal Biotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Krystal Biotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

The U.S. Food and Drug Administration approved a gene therapy for dystrophic epidermolysis bullosa, also known as butterfly disease.

Upgrades

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted  Priority Review designation and assigned a target actin date of February 17,…

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of patients with dystrophic epidermolysis bullosa (DEB).

A Relative Strength Rating upgrade for KrystalBiotech shows improving technical performance.

KrystalBiotech sees its Relative Strength Rating enter the elite 90-plus level.

Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities.